Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nls Pharmaceutics Ltd (NQ: NLSP ) 4.875 UNCHANGED Streaming Delayed Price Updated: 3:34 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nls Pharmaceutics Ltd < Previous 1 2 3 4 5 6 7 Next > Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday August 31, 2023 It's time for another breakdown of the biggest pre-market stock movers as we dive into all of the latest news for Thursday! Via InvestorPlace NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter August 28, 2023 NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) recently released a comprehensive shareholder letter by its CEO, Alex Zwyer, detailing recent achievements and ongoing endeavors. Via Benzinga NLS Pharmaceutics CEO Issues Letter to Shareholders August 28, 2023 Via ACCESSWIRE Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday August 23, 2023 It's time for another dive into the biggest pre-market stock movers as we break down all of the biggest news on Wednesday! Via InvestorPlace NLS Pharmaceutics Company Update and Webcast Today Postponed June 30, 2023 Via ACCESSWIRE Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 26, 2023 Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger. Via Benzinga Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session July 07, 2023 Gainers Prestige Wealth Inc. (NASDAQ: PWM) shares jumped 65.6% to $8.28. Prestige Wealth reported pricing of $5 million initial public offering of 1 million shares of common stock at a price of $5 per... Via Benzinga NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol July 03, 2023 Via ACCESSWIRE NLS Pharmaceutics Releases the Results from its Annual General Meeting June 30, 2023 Via ACCESSWIRE CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest June 19, 2023 Via ACCESSWIRE NLS Pharmaceutics Announces Company Update Webcast June 19, 2023 Via ACCESSWIRE NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest June 15, 2023 Via ACCESSWIRE NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol June 14, 2023 Via ACCESSWIRE NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer May 08, 2023 Via ACCESSWIRE NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023 May 04, 2023 Via ACCESSWIRE NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy May 02, 2023 Via ACCESSWIRE NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology April 25, 2023 Via ACCESSWIRE Why Did Bullfrog AI Stock Jump More Than 50%? April 05, 2023 Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University. Via MarketBeat Topics Artificial Intelligence Initial Public Offering Exposures Artificial Intelligence Securities Market NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2 March 27, 2023 Via ACCESSWIRE NLS Pharmaceutics to Present at the 35th Annual Roth Conference March 01, 2023 Via ACCESSWIRE NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy January 30, 2023 Via ACCESSWIRE NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement January 25, 2023 Via ACCESSWIRE NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity January 23, 2023 Via ACCESSWIRE Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session January 17, 2023 Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... Via Benzinga NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds January 12, 2023 Via ACCESSWIRE NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement January 12, 2023 Via ACCESSWIRE NLS Pharmaceutics to Participate in Upcoming Investor Conferences January 11, 2023 Via ACCESSWIRE NLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong January 10, 2023 Via ACCESSWIRE NLS Pharmaceutics CEO Issues Letter to Shareholders December 22, 2022 Via ACCESSWIRE NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037 December 20, 2022 Via ACCESSWIRE < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.